FDA Grants Priority Review to Inavolisib for Advanced HR+/HER2- Breast Cancer

Wednesday, 29 May 2024, 02:12

The FDA has granted priority review to Genentech's Inavolisib for the treatment of advanced hormone receptor-positive (HR+), HER2-negative breast cancer in patients with a PIK3CA mutation. This designation signifies the potential for a significant advancement in the treatment landscape for this specific subset of breast cancer patients. If approved, Inavolisib could offer a targeted therapy option with potentially positive outcomes.

https://store.livarava.com/2d2790cd-1d7c-11ef-a3de-9d5fa15a64d8.jpg — FDA Grants Priority Review to Inavolisib for Advanced HR+/HER2- Breast Cancer

FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Related posts